Skip to main content
Caplight Logo









Sydnexis

Sydnexis

Private
Del Mar, CaliforniaHealthcare & Life Scienceshttps://sydnexis.com/

Last Round

VC Round

Apr 15, 2025

Total Funding Raised

$50.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sydnexis is a biopharmaceutical company that develops topical ophthalmic formulations, including its lead candidate SYD-101, aimed at slowing the progression of pediatric myopia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

pediatric myopiamyopia managementlow-dose atropineophthalmic solutionmyopia controlclinical-stage biopharmadrug licensingphase 3 clinical trialnearsightedness treatmentophthalmologyoptometrybiotech startupeye care innovation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sydnexis Comparables

Compare Sydnexis with similar companies based on industry and business-model similarity.

Sydnexis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nevakar Inc.
92%
Eyenovia
82%
iVeena Delivery Systems
79%

Sydnexis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2025
Series BAug 10, 2021
Series AOct 19, 2017

Sydnexis Investors

Notable investors and investment history

Sydnexis investors
InvestorRounds
Longitude CapitalSeries A, Series B
RA Capital ManagementSeries A, Series B
SC Master FundSeries B
Visionary VenturesSeries B
MedicxiSeries A, Series B
Bluestem CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 162% MoM.

  • Mar 23, 2026

    Presented Phase 3 STAR Trial data at the 2026 AAPOS Annual Meeting.

Recent news

Latest coverage and updates

  • sells_assets_toSep 22, 2026

    Sydnexis sold assets to Ligand Pharmaceuticals Incorporated in the amount of $23M on Sep 22nd '26.

Sydnexis Filings

Explore SEC and related filing metadata, where available.

Sydnexis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sydnexis's valuation, stock price, and market status.

Is Sydnexis a public or private company?

Sydnexis is a private company.

What is the current stock price of Sydnexis?

Sydnexis is a private company with no public stock price. No recent secondary market data is available.

How much is Sydnexis worth (valuation)?

Valuation information for Sydnexis is not publicly available.

Can I buy Sydnexis stock?

Sydnexis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sydnexis's last funding round?

Sydnexis's most recent funding round was Series B on August 10, 2021.

Who are the main investors in Sydnexis?

Key investors in Sydnexis include SC Master Fund, Visionary Ventures, Bluestem Capital.

Will Sydnexis IPO soon?

No public IPO plans have been announced for Sydnexis.

How can I track Sydnexis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sydnexis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDel Mar, California
Employee Range13
Year Founded2014
Last FundingApr 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?